Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Arbutus Biopharma Corp ABUS

Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company. The Company is leveraging its virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can potentially be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV) infection. Its HBV product pipeline includes Imdusiran and AB-101. Imdusiran is its proprietary, conjugated GalNAc, subcutaneously delivered RNAi therapeutic product candidate. AB-101 is an oral PD-L1 inhibitor that has the potential to reawaken patients’ HBV-specific immune response by inhibiting PD-L1. Its pipeline includes two product candidates that target various steps in the HBV viral lifecycle and consists of various programs: RNAi therapeutic (imdusiran, AB-729) and Oral PD-L1 Inhibitor (AB-101). RNAi therapeutics utilize a natural pathway within cells to silence genes by eliminating the disease-causing proteins that they code for.


NDAQ:ABUS - Post by User

Bullboard Posts
Comment by TimeScapeon Mar 04, 2014 6:48pm
240 Views
Post# 22280319

RE:Lots of volatility lately

RE:Lots of volatility lately
Looking at the long term chart, I mentioned here a while back that $20 was a resistance point, and then nothing much until $40. It broke through $20 pretty easily, and has now moved back to test the breakout. The $20 level has held so far and is now starting to look like support. I still think $40 is the next target, which would be a market cap of about $800 million, and I don't think that is out of line given the new agro market potential in addition to the medical. No idea on the timing, although I think 3-6 months is probably too short a time frame to get to that level. The recent highs in the $27 range may be more of target in that short a time frame. Of course, if the market has a significant correction, then TKM will take a hit. Q2 and Q3 of year 2 of the US presidential cycle are the worst for the stock market, so I wouldn't be surprised to see a weak stock market between April and September.
Bullboard Posts